The most successful method to date uses the N-acetylgalactosamine (GalNAc) ligand which, when conjugated to RNA moieties, allows cellular uptake, but only into liver hepatocytes. A few RNA ...

The University of Chicago team found that by attaching a sugar protein, N-acetylgalactosamine (pGal), to the self-antigen under assault, they could send it to the liver, which would teach the ...

Under the first two agreements, insitro has an option to in-license proprietary, clinical stage, ternary N-acetylgalactosamine (GalNAc) delivery technology from Lilly that it will combine with two ...

A very large family of ppGalNAc transferases (>16) initiates mucin-type O-glycan by adding N-acetylgalactosamine (GalNAc) to peptide Ser and Thr residues. Homologous family members are found over a ...

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV ...

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV ...

To demonstrate how this can work, Andersson pointed to results from a study into the targeted delivery of a promising liver-targeted N-acetylgalactosamine (GalNAc) conjugated antisense ...

Imdusiran targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology enabling subcutaneous delivery. Clinical data generated thus far has ...

Imdusiran targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology enabling subcutaneous delivery. Clinical data generated thus far has shown ...

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting ...